Novo Nordisk's obesity pill is outperforming Eli Lilly's in the weight-loss drug market, where Lilly leads in injectables but lags in pills.
WSJ07/15, 07:00 AM
Related assets
Coming up for NVO
Explore next
Latest NVO news
MarketWatch08/27, 03:37 PM
Deutsche Bank downgraded Novo Nordisk to sell after the stock fell 70% from its peak.
Jin1008/27, 10:33 AM
Novo Nordisk has applied for approval of an oral formulation of Wegovy for weight management.
Finnhub08/19, 05:10 PM